profit from every $100 of sales.
$0$100
Utah Medical Products
$72.87+0.89% today
+27.0% in 1 year
1-year low $53.801-year high $76.66
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $18.38 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Utah Medical Products sold, what it kept, and what it did with the cash.
Sales went from $52.3 million in 2022 to $38.5 million in 2025, with $11.3 million of profit last year.
SalesProfit
Utah Medical Products handed back 86% of the cash it generated last year.
Buybacks $8M$4M
Free cash flow 2025$14M
Bought back its own shares$8M
Paid as dividends$4M
Cash vs. debt$86M vs. $225,000
Utah Medical Products vs. similar companies
Utah Medical Products grows the slowest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Utah Medical Products | 18.4× · Fair price | ||
 ResMed | 21.8× · Fair price | ||
 West Pharmaceutical Services | 58.3× · Expensive | ||
 Hologic | 30.0× · Fair price | ||
 Baxter International | No profit yet |
AI analysis
An AI analyst reads Utah Medical Products's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 52 | 50 | 41 | 39 | |
| 32 | 30 | 24 | 22 | |
| 20 | 17 | 14 | 11 | |
| 27 | 23 | 16 | 14 | |
| 16 | 17 | 14 | 11 | |
| 4.52 | 4.57 | 3.96 | 3.48 | |
| 61.6% | 59.8% | 59.0% | 57.1% | |
| 37.9% | 33.4% | 33.2% | 29.6% | |
| 31.5% | 33.1% | 33.9% | 29.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 124 | 135 | 123 | 123 |
| Cash | 75 | 93 | 83 | 86 |
| Total debt | 0 | 0 | 0 | 0 |
| Total liabilities | 10 | 7 | 5 | 3 |
| 114 | 128 | 117 | 119 | |
| 4 | 4 | 4 | 3 | |
| 13.6% | 10.3% | 9.1% | 7.5% | |
| 14.4% | 13.0% | 11.8% | 9.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 21 | 22 | 15 | 15 | |
| 1 | 1 | 0 | 0 | |
| 20 | 22 | 15 | 14 | |
| Dividends paid | 3 | 4 | 4 | 4 |
| 2 | 0 | 20 | 8 | |
| 0 | 0 | 0 | 0 |
Valuation
- 18.4×
- –
- –
- 1.7×
- 5.4×
- 14.5×
- 8.5×
- 6.9%
- 5.4%
- 1.9%
Profitability
- 57.1%
- 29.6%
- 29.3%
- 40.1%
- 7.2%
- 12.5%
- 9.1%
- 8.7%
- 8.9%
- 1.8%
Growth
- −9.7%
- −8.3%
- −1.9%
- +1.7%
- −2.4%
Financial health
- -5.8×
- 0.00
- 0.2%
- –
- 28.64
- 26.15
- 0.30
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 41%of 948
Top 10%of 871
Top 27%of 560
Bottom 8%of 868
Top 12%of 985
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 23, 2026 | 0.82 | – | – |
| Jan 29, 2026 | 0.80 | – | – |
| Oct 23, 2025 | 0.82 | – | – |
| Jul 24, 2025 | 0.94 | – | – |
| Apr 29, 2025 | 0.92 | – | – |
| Mar 26, 2025 | 0.86 | – | – |
| Oct 29, 2024 | 1.02 | – | – |
| Jul 25, 2024 | 0.98 | – | – |
1.9%of the share price, paid each year
On $1,000 invested$19a year at today's yield, before tax
+1.7%2020 to 2025
Raised3 yearsin a row, in our data
Paid per share, each year
$1.03 in 2015 → $1.23 in 2025
How safe it looks
35.3% of its profit
Room to growStretchedMore than it earns: 27.8%
News
Fervo Energy reaches commercial operation at Utah geothermal plantSeeking Alpha · Oct 1, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
5/7Passes 5 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
69Pass
Benjamin Graham
81Pass
Philip Fisher
70Pass
Peter Lynch
35No pass
Joel Greenblatt
44No pass
Charlie Munger
72Pass
Terry Smith
65Pass
Questions about Utah Medical Products
Is Utah Medical Products a good stock to buy?
A strong, very profitable business at a fair price. 5 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Utah Medical Products AI analysis
What does Utah Medical Products do?
Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry. It is in Medical - Instruments & Supplies.
Does Utah Medical Products pay a dividend?
Yes. At today's price the dividend is 1.9% a year, about 35% of its yearly profit. In 2025 it paid out $3.98 million in dividends.
Is Utah Medical Products stock halal?
No. Utah Medical Products does not pass our halal screen: its cash and confirmed interest-bearing investments are 41% of its market value, at or above the 33% limit. How we check
How has Utah Medical Products stock done over the past year?
Up 27.0% over the past twelve months, to $72.87. It traded between $53.80 and $76.66 and is 4.9% below its high.
Who are Utah Medical Products's competitors?
The largest listed companies in the same industry are ResMed, West Pharmaceutical Services, Hologic and Baxter International. The peers table on this page compares their profit, growth and price with Utah Medical Products's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.